Chandra Mohan Selected Research

Nuclear Antigens (Extractable Nuclear Antigens)

11/2012	Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.
12/2011	Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps.
1/2011	Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models.
6/2010	Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chandra Mohan Research Topics

Disease

44	Lupus Nephritis 01/2022 - 08/2002
42	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 05/2005
29	Nephritis 01/2022 - 01/2006
26	Proteinuria 01/2022 - 04/2003
21	Glomerulonephritis 01/2022 - 08/2002
21	Inflammation (Inflammations) 02/2021 - 08/2010
13	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 05/2005
6	Chronic Renal Insufficiency 03/2020 - 01/2011
6	Rheumatoid Arthritis 01/2020 - 07/2010
6	Poisoning 01/2018 - 01/2015
5	Splenomegaly 01/2022 - 04/2009
5	Neoplasms (Cancer) 01/2021 - 11/2012
5	Anti-Glomerular Basement Membrane Disease (Goodpasture's Syndrome) 06/2016 - 04/2005
4	Rheumatic Diseases (Rheumatism) 05/2019 - 01/2007
4	Azotemia 02/2011 - 04/2004
3	Kidney Diseases (Kidney Disease) 01/2022 - 01/2014
3	Systemic Scleroderma (Systemic Sclerosis) 12/2019 - 11/2015
3	Hyperphosphatemia 02/2016 - 01/2011
3	Interstitial Nephritis (Tubulointerstitial Nephritis) 02/2011 - 04/2003
2	Fatty Liver 03/2022 - 02/2021
2	Non-alcoholic Fatty Liver Disease 03/2022 - 02/2021
2	Urinary Bladder Neoplasms (Bladder Cancer) 04/2021 - 01/2019
2	Obesity 02/2021 - 03/2009
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021 - 07/2019
2	Ulcerative Colitis 01/2021 - 05/2019
2	Acute Kidney Injury (Acute Renal Failure) 03/2020 - 01/2018
2	Osteoarthritis 05/2019 - 09/2017
2	Pneumonia (Pneumonitis) 01/2019 - 10/2014
2	Hypophosphatemia 01/2018 - 01/2011
2	Necrosis 11/2017 - 01/2015
2	Fibrosis (Cirrhosis) 11/2017 - 02/2015
2	Diabetic Nephropathies (Diabetic Nephropathy) 01/2016 - 01/2015
2	Disease Progression 06/2015 - 01/2012
2	Lung Injury 02/2015 - 01/2015
2	Chronic Disease (Chronic Diseases) 08/2012 - 07/2010

Drug/Important Bio-Agent (IBA)

45	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2007
29	AutoantibodiesIBA 03/2020 - 08/2002
18	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2007
15	antiglomerular basement membrane antibodyIBA 02/2021 - 04/2004
10	CytokinesIBA 01/2020 - 01/2005
10	Immunoglobulin G (IgG)IBA 01/2020 - 08/2002
9	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022 - 03/2007
8	CreatinineIBA 01/2022 - 09/2011
8	Urea (Carbamide)FDA LinkGeneric 03/2020 - 04/2003
8	NitrogenIBA 03/2020 - 04/2003
8	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 08/2002
7	AntibodiesIBA 11/2020 - 02/2005
6	Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA 01/2022 - 01/2020
6	Ferritins (Ferritin)IBA 08/2021 - 08/2012
6	ParaquatIBA 01/2018 - 01/2015
5	TeaIBA 03/2022 - 09/2011
5	anti-dsDNA autoantibodyIBA 01/2022 - 02/2005
4	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 03/2022 - 01/2015
4	AngiostatinsIBA 01/2022 - 05/2013
4	Lipocalin-2IBA 01/2022 - 06/2012
4	AntigensIBA 01/2020 - 01/2009
4	ChemokinesIBA 01/2019 - 03/2007
4	LigandsIBA 11/2018 - 07/2012
4	Nuclear Antigens (Extractable Nuclear Antigens)IBA 11/2012 - 06/2010
3	PolyphenolsIBA 03/2022 - 09/2011
3	Therapeutic UsesIBA 03/2022 - 01/2013
3	LipidsIBA 03/2022 - 01/2012
3	Blood Proteins (Serum Proteins)IBA 08/2021 - 01/2016
3	CollagenIBA 02/2021 - 04/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 10/2011
3	Pharmaceutical PreparationsIBA 01/2020 - 08/2010
3	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 09/2007
3	Peptides (Polypeptides)IBA 01/2020 - 04/2009
3	Biological ProductsIBA 05/2019 - 10/2011
3	Kallikreins (Kallikrein)IBA 03/2013 - 04/2009
3	Antinuclear AntibodiesIBA 03/2012 - 05/2005
2	Catechin (Z 7300)IBA 03/2022 - 07/2019
2	Antigen-Antibody Complex (Immune Complex)IBA 01/2022 - 01/2022
2	Complement C3 (C3 Complement)IBA 01/2022 - 01/2022
2	Immunoglobulin M (IgM)IBA 01/2022 - 08/2002
2	Interleukin-8 (Interleukin 8)IBA 04/2021 - 01/2021
2	HaptoglobinsIBA 01/2021 - 01/2021
2	Fibrinogen (Factor I)FDA Link 01/2021 - 01/2021
2	Peroxidase (Myeloperoxidase)IBA 01/2021 - 01/2021
2	Interleukin-15 (Interleukin 15)IBA 01/2021 - 01/2019
2	CurcuminIBA 03/2020 - 05/2019
2	BradykininIBA 01/2020 - 01/2019
2	AutoantigensIBA 01/2020 - 06/2010
2	SteroidsIBA 01/2020 - 01/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2019 - 10/2011
2	CXC ChemokinesIBA 11/2018 - 04/2003
2	Interferon Type IIBA 12/2017 - 11/2009
2	Complement System Proteins (Complement)IBA 12/2017 - 01/2016
2	Fish OilsIBA 09/2017 - 08/2015
2	Amyloid (Amyloid Fibrils)IBA 01/2017 - 02/2010
2	Prostaglandins AIBA 01/2016 - 08/2015
2	AntioxidantsIBA 08/2015 - 01/2015
2	pristane (pristan)IBA 02/2015 - 09/2013
2	Toll-Like Receptors (Toll-Like Receptor)IBA 02/2015 - 12/2012
2	InterferonsIBA 02/2015 - 10/2011
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2014 - 01/2011
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 07/2012 - 04/2003
2	Indicators and Reagents (Reagents)IBA 07/2012 - 03/2007
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 07/2012 - 01/2007

Therapy/Procedure

9	Therapeutics 05/2019 - 08/2007